Imperagen appoints Guy Levy-Yurista as CEO after £5M seed round for AI enzyme engineering.
The AMW Read
Incremental update: Seed-stage AI biology company appoints CEO; no structural shift, segment-level impact limited to one emerging player.
Imperagen appoints Guy Levy-Yurista as CEO after £5M seed round for AI enzyme engineering.
Manchester-based techbio company Imperagen has appointed Guy Levy-Yurista as CEO following a £5 million (~$6.3M) seed funding round. The company uses AI and quantum physics to engineer enzymes for industrial applications. Levy-Yurista previously led Synthace, where he helped secure $45 million in funding, and held senior roles at Sisense and MicroStrategy.
Why it matters: Imperagen is building what it calls a "Large Catalytic Model" for biocatalysis, applying AI foundation-model techniques to enzyme engineering — a segment where we've seen early-stage companies like Cradle and Profluent emerge. This appointment signals a shift from R&D to commercial scaling, a pattern we track as 'deep-tech commercialization risk' in our vertical substrate. The seed round is modest compared to later-stage peers, reflecting the capital-compression arc currently affecting European deep-tech.
Grounded expert take: The appointment of a CEO with SaaS and enterprise-AI scaling experience, rather than a pure scientific founder, mirrors the pattern we saw at Synthace — a pivot from platform to product-led growth. For Imperagen, the challenge will be proving that its AI-powered enzyme design can deliver real-world replacements for petrochemical catalysts, a notoriously slow-adoption industrial market. The 'Large Catalytic Model' framing borrows from the foundation-model playbook, but the company must demonstrate unit economics that beat traditional directed evolution.
